iiinova — where your digital self keeps evolving

A-TANGO Project @a-tango.bsky.social · 13/07/2026

📣 A major milestone for the A-TANGO project: The first patient with #ACLF has started treatment in the Phase 2 trial evaluating the investigational #G-TAK combination therapy. A crucial step towards developing new treatment options for this life-threatening condition! 🔗 a-tango.eu/wp-content/u...

052

A-TANGO Project @a-tango.bsky.social · 31/05/2026

👏 3 more outstanding posters 📣 from the coordinating institute UCL at #EASLCongress 2026 - great job, Supacha & Jinxia! 1️⃣ Ammonia-induced bioenergetic failure via #TLR4🔋 2️⃣ YAQ006 and YAQ005 reduce mortality in #ACLF☠️ 3️⃣ Yaq-001 ameliorates liver injury via gut #microbiome🦠 @rajivjalan.bsky.social

042

A-TANGO Project @a-tango.bsky.social · 31/05/2026

💫 Three outstanding Charité posters at #EASLCongress 2026 in Barcelona - well done, Sina, Joscha & Alex! 1️⃣ Body composition & survival in HRS-AKI 2️⃣ Macrophages & gut barrier failure in alcoholic hepatitis🍷 3️⃣ Thrombin generation🩸in #cirrhosis & #ACLF @easlnews.bsky.social @europeliver.bsky.social

073

A-TANGO Project @a-tango.bsky.social · 29/05/2026

🌍 Which #ACLF score performs best? In 3,370 COSSH cohort patients, the A-TANGO score matched the COSSH-ACLF Score for ACLF diagnosis + short-term #mortality prediction, while other models markedly underestimated ACLF. 👉 Visit Meiqian Hu's poster tomorrow! 🔍 #Poster SAT-476 @rajivjalan.bsky.social

042

A-TANGO Project @a-tango.bsky.social · 29/05/2026

🧪 A deep dive into basic & translational science: Minneke Coenraad (LUMC) chaired today's last #PosterTour on "Experimental and Pathophysiology" at the Cirrhosis & Complications Track Hub! 💫 Meiqian Hu from Rajiv Jalan's group (UCL) did a fantastic job presenting her poster! #EASLCongress #EASL2026

142

A-TANGO Project @a-tango.bsky.social · 29/05/2026

🤩 Great attendance & active discussion at #EASLCongress today! Very insightful & interactive Networking Session on the evolving definition and #RiskStratification of ACLF, highlighting the new #ATANGOscore & the urgent need for international #Harmonisation of #ACLF criteria. @rajivjalan.bsky.social

042

A-TANGO Project @a-tango.bsky.social · 29/05/2026

At today’s J Hep Symposium, Benedikt Hofer (author) & Annalisa Berzigotti (challenger) discussed abstinence-induced #Recompensation in #Alcohol-related #Cirrhosis, chaired by Frank Tacke (Charité). 👉 Sustained abstinence = lower mortality 🍷⛔ #EASLCongress #LiverDisease @jhepatology.bsky.social

042

A-TANGO Project @a-tango.bsky.social · 28/05/2026

🧬 Novel #biomarker composites may help predict #AKI and #mortality following acute decompensation of #cirrhosis. 📍Presented in #POSTER WED-448-YI by Olivia Greenham et al. during #EASLCongress 2026! #RiskStratification #LiverDisease #Patients @europeliver.bsky.social @rajivjalan.bsky.social

082

A-TANGO Project @a-tango.bsky.social · 28/05/2026

🧬 Genetic #Cholestasis in adults: When to test? That's the question A-TANGO consortium member Thomas Berg asked today as chair + speaker in the Ipsen Symposium "Rare Genetic #LiverDiseases - Bridging the Gap from #GeneticTesting to #PatientManagement". #EASL2026 #RareDiseases @easlnews.bsky.social

041

A-TANGO Project @a-tango.bsky.social · 28/05/2026

🧠 The modified hepatic encephalopathy staging tool (mHEST) outperformed West Haven criteria in diagnostic consistency and prognostic performance. #POSTER TOP-471-YI by Annarein Kerbert et al. #EASL2026 #HepaticEncephalopathy #Cirrhosis #Hepatology @rajivjalan.bsky.social @europeliver.bsky.social

083

A-TANGO Project @a-tango.bsky.social · 23/05/2026

📣 SNEAK PEEK 🔍 of posters, talks, networking sessions & chairing activities by Consortium Members during #EASLCongress next week (27-30 May 2026) in Barcelona! #ACLF #cirrhosis #LiverDisease #LiverFailure #Hepatology #LiverSky @rajivjalan.bsky.social @europeliver.bsky.social @easlnews.bsky.social

053

A-TANGO Project @a-tango.bsky.social · 23/05/2026

🥳 Join the A-TANGO Networking Session at #EASLCongress! 🗓 Fri, 29 May 2026 ⏰ 10:00–10:30 📍 Cirrhosis & Complications Track Hub 6 The A-TANGO Score: A Novel Tool for Risk Stratification & #ClinicalEndpoints in #ACLF @rajivjalan.bsky.social @easlnews.bsky.social @europeliver.bsky.social

054

A-TANGO Project @a-tango.bsky.social · 14/04/2026

🥳 How are you planning to celebrate #WorldLiverDay? And what do you do to strengthen your own liver? #SolidHabitsStrongLiver 👉 Eat healthy - daily 🥦 👉 Move your body - daily 🥎🎾🏃‍➡️ 👉 Reduce alcohol - always🍷 ➡️ 🥛 (there is no "safe" amount of alcohol) 👉 Get your liver checked regularly by a doctor 🩺

031

A-TANGO Project @a-tango.bsky.social · 02/04/2026

📣 IMAC invites you to an upcoming webinar examining how evidence in rare disease trials can be interpreted more rigorously. 🎓 𝗙𝗿𝗼𝗺 𝗙𝘂𝘁𝗶𝗹𝗶𝘁𝘆 𝘁𝗼 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴: 𝗪𝗵𝗮𝘁 𝗮 𝗕𝗮𝘆𝗲𝘀𝗶𝗮𝗻 𝗟𝗲𝗻𝘀 𝗥𝗲𝘃𝗲𝗮𝗹𝘀 𝗶𝗻 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗧𝗿𝗶𝗮𝗹𝘀 📅 April 9 ⏰ 4:00 pm CET 👉 Register here: events.teams.microsoft.com/event/9ed2de...

041

A-TANGO Project @a-tango.bsky.social · 09/01/2026

🚀 Motivation boost to kick off the new year 🙂: The European Commission agreed to provide a 6-month-long extension to A-TANGO! Let's use this momentum and move forward swiftly now, so that A-TANGO can bring the much-needed G-TAK therapy for severe #AlcoholicHepatitis #cirrhosis #ACLF to the market.

142

A-TANGO Project @a-tango.bsky.social · 22/12/2025

🥂 We have good news for the holidays: The technical hold-up in the EU portal has finally been resolved & we submitted the 3rd #PeriodicReport ☺️ Wishing everyone relaxing holidays❄️ Together, we are moving from bench to bedside to bring innovative therapies to #ACLF patients @rajivjalan.bsky.social

042

A-TANGO Project @a-tango.bsky.social · 04/10/2025

👏 1st Site Visit Completed for A-TANGO's #ClinicalTrial: Thanks to big efforts by Yaqrit + Royal Free Hospital, we have kicked off our Phase 2a trial, evaluating the safety of #TLR4 antagonist in combination with #G-CSF for the treatment of #ACLF! #BenchToBedside #cirrhosis @rajivjalan.bsky.social

031

A-TANGO Project @a-tango.bsky.social · 28/07/2025

For #WorldHepatitisDay we stand together 🩺 At A‑TANGO, we aim to transform healthcare for people with #LiverDisease, including those living with #cirrhosis and #ACLF, putting #patients first ☺️ Every person deserves timely, effective, and #stigma‑free support 💪 @europeliver.bsky.social @who.int

074

A-TANGO Project @a-tango.bsky.social · 25/06/2025

What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊 #AlcoholicHepatitis @europeliver.bsky.social @easlnews.bsky.social

084

A-TANGO Project @a-tango.bsky.social · 28/05/2025

Join this exciting event! Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities! 🚀 Register now: inevent.uk/en/Crowdheli...

063

A-TANGO Project @a-tango.bsky.social · 20/05/2025

📣 Secure your spot now 📣: inevent.uk/en/Crowdheli... Check out our upcoming (online) A-TANGO #LiverHealth Helix Event! 🟣 Industrial Perspective on #DrugDevelopment Challenges for #ClinicalTrials 🗓️ 04 June 2025 🕙 Begin: 10 am BST #ClinicalResearch @rajivjalan.bsky.social @easlnews.bsky.social

152

A-TANGO Project @a-tango.bsky.social · 12/05/2025

✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement. 🗓️ What a fun #workshop at #EASLCongress 2025

173

A-TANGO Project @a-tango.bsky.social · 10/05/2025

🧠 SAT-210 – #EASL2025 New tool alert! The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team! #LiverHealth #HE #ClinicalResearch

053

A-TANGO Project @a-tango.bsky.social · 10/05/2025

🧪 SAT-209 – #EASL2025 MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis

053

A-TANGO Project @a-tango.bsky.social · 10/05/2025

👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress 👉 Is #alcohol-related #hepatitis in ACLF its own beast? 👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis? Chair @rajivjalan.bsky.social

052

A-TANGO Project @a-tango.bsky.social · 10/05/2025

👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏 🥳 TOP-217-YI 🥳 Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications

052

A-TANGO Project @a-tango.bsky.social · 09/05/2025

Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress: FRI-197 The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium Crucial for understanding the disease progression! @rajivjalan.bsky.social

052

A-TANGO Project @a-tango.bsky.social · 09/05/2025

🌟 POSTER THU-182 by Supachaya S. (UCL, @rajivjalan.bsky.social) featured in a #PosterTour at #EASLCongress! 👏 👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate 👍 In A-TANGO, we use #TAK242 + G-CSF

052

A-TANGO Project @a-tango.bsky.social · 08/05/2025

🎬 Summary #movie of A-TANGO's Investigator & Industry Session 🥂 at #EASLCongress. Big thanks to Yaqrit for sponsoring this inspiring event. Let's roll up our sleeves now to start the #GTAK trial in the UK, and hopefully also in India + Germany & other EU countries 🩺 ☺️! #ACLF #cirrhosis #LiverFailure

052

A-TANGO Project @a-tango.bsky.social · 08/05/2025

💲💰 Wake up your inner #entrepreneur, found your own start-up #company #business, and learn from expert @rajivjalan.bsky.social about how to manage financial conflicts of interest #COI Today at #EASLCongress as part of a #YoungInvestigator Seminar! 📍 Erlinger Room 📅 Thurs, May 8 ⏲️ 15:35 - 15:45 h

052

A-TANGO Project @a-tango.bsky.social · 08/05/2025

📣 Today: #POSTER TOP-203, congrats 🥳 A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL 👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF 👉 Topic: Cirrhosis & Complications #LiverFailure #ACLF @rajivjalan.bsky.social

052

A-TANGO Project @a-tango.bsky.social · 08/05/2025

📣 Another top-notch #poster at the very heart of A-TANGO is THU-180-YI by Supachaya Sriphoosanaphan, UCL 👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction #Cirrhosis & Complications #ACLF #LiverFailure @rajivjalan.bsky.social

052

A-TANGO Project @a-tango.bsky.social · 08/05/2025

📣 Two fantastic #posters today - visit them before 5 pm! Both by Supachaya Sriphoosanaphan, UCL 👉 THU-182 Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate 👉 #Cirrhosis & Complications #ACLF #LiverFailure

052

A-TANGO Project @a-tango.bsky.social · 08/05/2025

TODAY - catering provided🍎🥂 - just come by - still spots open, no registration needed ✅ A-TANGO #Investigator & #Industry Session 👉 Thurs, 8 May 👉 5-7 pm at #EASLCongress 🚨 Important: Access Room D202, Elicium Building (level 2), via bridge from main level #ACLF #cirrhosis #LiverFailure #GTAK

152

A-TANGO Project @a-tango.bsky.social · 07/05/2025

🎙️ Talking #ACLF with #patients! The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience 🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients @europeliver.bsky.social @rajivjalan.bsky.social

083

A-TANGO Project @a-tango.bsky.social · 07/05/2025

👏 Our superstar Julian Pohl (Charité) is not only active in ACLF research but also brings 🧪 #suPAR & #MASLD into the spotlight! His poster WED-437 at #EASLCongress this year shows it can identify at-risk patients - a game-changer for non-invasive #diagnostics. #LiverDisease #biomarkers #metabolism

051

A-TANGO Project @a-tango.bsky.social · 25/04/2025

Hope for #ACLF patients is on the horizon! Join the A-TANGO Patient Event at #EASLCongress: 📅 Wed, 7 May 2025 🕑 14:00–15:00 📍 Room D202, Elicium Building, Level 2 Learn about A-TANGO, the G-TAK trial and join the discussion on improving #patient outcomes. #LiverDisease @europeliver.bsky.social

075

A-TANGO Project @a-tango.bsky.social · 25/04/2025

Let’s talk #inflammation, #alcohol-related #hepatitis and new treatment strategies at #EASLCongress 👉 A-TANGO Networking Session 🗓️ Sat, 10 May 2025, 9:45–10:15 📍 Cirrhosis & Complications Track Hub These short networking sessions are lots of fun! @easlnews.bsky.social #hepatology #cirrhosis #ACLF

075

A-TANGO Project @a-tango.bsky.social · 25/04/2025

👉 Please register now: docs.google.com/forms/d/e/1F... Join us for the A-TANGO #Investigator & #Industry Session on Thursday, 8 May, from 5-7 pm at #EASLCongress. You can participate in person or online (Zoom Link will be set via email). #cirrhosis #LiverFailure #GTAK ✔️ Food & drinks provided 🥂

085

A-TANGO Project @a-tango.bsky.social · 27/03/2025

👏 Whohoo! More than 300 experts from 140 organisations in 38 countries have joined the Liver Health Helix. Launched in 2021 to support A-TANGO's dissemination and impact, it is a community of #hepatology #LiverDisease #cirrhosis & #bioinformatics specialists. Join now: platform.crowdhelix.com/login

074

A-TANGO Project @a-tango.bsky.social · 27/03/2025

🩺 Who conducted the 1st #ClinicalTrial can be debated, but historical records suggest it happened in biblical times. Cornelius Engelmann (Charité), who supervises A-TANGO's clinical #GTAK trial, held an all-encompassing #Masterclass on Wed, 26 March 2025. #LiverFailure #ACLF #CombinatorialTherapy

163

A-TANGO Project @a-tango.bsky.social · 03/02/2025

📣 Welcome Troels Jordansen as the new CEO of Yaqrit! With over 30 years of international experience in pharmaceuticals, medical devices, cellular therapy, and biotech, Troels has a strong background in #sales, #marketing, #InvestorRelations, and #BusinessDevelopment. 💪 📰 yaqrit.com/_WPY2025/wp-...

072

A-TANGO Project @a-tango.bsky.social · 21/01/2025

📽️: youtu.be/7rnM-Cgl33U?... Watch our YouTube video with A-TANGO early-career scientists (ECS) Annarein Kerbert (MD, PhD) & Julian Pohl (MD) about #alcohol-related #LiverFailure vs. #infection-induced #ACLF at #EASLCongress 2024 #liversky @easlnews.bsky.social @ec.europa.eu @ebtapper.bsky.social

073

A-TANGO Project @a-tango.bsky.social · 16/01/2025

☺️ Welcome! 😊 You can now also follow us here on Bluesky. Spearheaded by EF CLIF, 13 partners joined forces for the A-TANGO project in March 2021 to develop G-TAK, a novel combinatorial therapy for #ACLF (acute-on-chronic #LiverFailure) by using the synergistic actions of G-CSF + TAK-242. #LiverSky

093